Kazakhstan has recorded a decrease in prices for a number of medicines subject to state regulation. The trend follows the introduction of an updated pricing mechanism designed to enhance transparency and predictability in the pharmaceutical market.
Currently, price caps are set for 4,994 medicinal products. An additional 1,707 over-the-counter medicines have been removed from state regulation and are sold at market prices, with continuous oversight from regulatory authorities.
In 2025, the Committee for Medical and Pharmaceutical Control conducted a price monitoring study across 20 regions, focusing on 50 high-demand medicines from five pharmacological groups: antivirals, anti-inflammatories, antibiotics, cardiovascular drugs, and gastrointestinal treatments.
The monitoring showed that prices decreased by 34% of the monitored medicines in September (an average of 7.8%) and by 50% in October (an average of 11.1%). The most notable reductions were observed for Hepar comp. Heel, Revmoxicam®, Cefyaps, VALMAK-N, and Zitmak®.
The Committee will continue systematic price monitoring to ensure access to quality and affordable medicines. Possible violations can be reported through the DariKZ and Naqty Ónim mobile apps or to regional departments.
Source: Ministry of Healthcare